TMCnet News
ArTara Therapeutics Announces Addition of Randall Marshall, MD as Chief Medical OfficerArTara today announces the appointment of Randall Marshall, MD as Chief Medical Officer and President of Research & Development. Dr. Marshall will join as a co-founder of ArTara to provide scientific and medical leadership for research and business development activities. Dr. Marshall brings over 30 years' experience across all aspects of clinical research including translational, Phase 1-3, and post-marketing studies in academia, start-up, and mid-sized biopharmaceutical companies. Prior to joining ArTara, Dr. Marshall led Retrophin, Inc.'s development of fosmetpantotenate, a replacement therapy for PKAN, an ultra-rare neurodegenerative disease. Under Dr. Marshall's leadership the program moved from first-in-man to pivotal trial in 2 years and was granted a special protocol assessment (SPA) from FDA. Dr. Marshall's previous experience includes leadership of multiple drug development programs at companies such as Neurovance, Alkermes and Sepracor/Sunovion. Dr. Marshall's career began in academia at Columbia University, where he was an Associate Professor specializing in clinical trials in CNS indications including PTSD. "We are excited for Randallto join ArTara," said Jesse Shefferman, Chief Executive Officer of ArTara Therapeutics. "He brings an impressive track record of creativity and success as a medical scientist and drug development expert in high growth biopharma companies. I look forward to his leadership and close partnership as we grow ArTara into a world-class clinical stage rare diseases company." "I am very excited to join ArTara at this early stage, as we move promising Phase 2 data in IV Choline onto a rapid development path to get patients with IFALD their first approved therapy," said Dr. Marshall. "We will build a company devoted to efficient development, with a culture that fosters the nuance, creativity, flexibility and compassion that rare disease development requires." About IV Choline Chloride (News - Alert): Our first program, IV Choline Chloride, has shown promising results in two Phase 2 studies in IFALD (Intestinal Failure Associated Liver Disease). IV Choline is a replacement therapy for patients on parenteral nutrition (PN) with choline deficiency. We are developing IV Choline in partnership with Dr. Alan Buchman, a leader in the field of gastroenterology and a key voice for the potential of choline as a therapy for IFALD. About Intestinal Failure Associated Liver Disease (IFALD): IFALD is a progressive liver disease that occurs in up to 65% of patients who are dependent on PN. There are as many as 25,000 PN patients in the US and ~10,000 in the EU. IFALD is characterized by accumulation of triglycerides in the liver leading to liver injury, cholestasis, and eventually a need for dual liver/intestine transplant or death. There are no approved therapies for IFALD. About ArTara Therapeutics - ArTara is a rare diseases therapeutics company focused on optimizing therapeutics for patients suffering from rare diseases where there is a significant unmet need. Our initial focus is on rare gastrointestinal, metabolic, circulatory and neurological disorders.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180108006976/en/ |
